Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2969)
All Articles published online
|
Dec 15, 2003 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Hua Z, Zhang YC, Hu XM, Jia ZG. Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. World J Gastroenterol 2003; 9(12): 2764-2767 [PMID: 14669329 DOI: 10.3748/wjg.v9.i12.2764] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v9/i12/2764.htm |
| Number | Citing Articles |
| 1 |
Genevieve M. Boland, Sarah P. Thayer. Pancreatic Cancer. 2008; : 181 doi: 10.1007/978-0-387-69252-4_11
|
| 2 |
Xing Shugang, Yang Hongfa, Liu Jianpeng, Zheng Xu, Feng Jingqi, Li Xiangxiang, Li Wei. Prognostic Value of SMAD4 in Pancreatic Cancer: A Meta-Analysis. Translational Oncology 2016; 9(1): 1 doi: 10.1016/j.tranon.2015.11.007
|
| 3 |
Shujie Zhao, Sudhakar Ammanamanchi, Michael Brattain, Lin Cao, Amalraj Thangasamy, Jing Wang, James W. Freeman. Smad4-dependent TGF-β Signaling Suppresses RON Receptor Tyrosine Kinase-dependent Motility and Invasion of Pancreatic Cancer Cells. Journal of Biological Chemistry 2008; 283(17): 11293 doi: 10.1074/jbc.M800154200
|
| 4 |
Yujun Gu, Yayun Ji, Hui Jiang, Ganbin Qiu. Clinical Effect of Driver Mutations of KRAS, CDKN2A/P16, TP53, and SMAD4 in Pancreatic Cancer: A Meta-Analysis. Genetic Testing and Molecular Biomarkers 2020; 24(12): 777 doi: 10.1089/gtmb.2020.0078
|
| 5 |
Atul Bhardwaj, William L. Marsh, Jr, Jason W. Nash, Catalin C. Barbacioru, Susie Jones, Wendy L. Frankel. Double Immunohistochemical Staining With MUC4/p53 Is Useful in the Distinction of Pancreatic Adenocarcinoma From Chronic Pancreatitis: A Tissue Microarray-Based Study. Archives of Pathology & Laboratory Medicine 2007; 131(4): 556 doi: 10.5858/2007-131-556-DISWPI
|
| 6 |
Aarti Mathur, Martha A. Zeiger. Genomic medicine for cancer prognosis. Journal of Surgical Oncology 2015; 111(1): 31 doi: 10.1002/jso.23734
|
| 7 |
Joseph M. Herman, Salma K. Jabbour, Steven H. Lin, Matthew P. Deek, Charles C. Hsu, Elliot K. Fishman, Sinae Kim, John L. Cameron, Marina Chekmareva, Daniel A. Laheru, Amol K. Narang, Timothy M. Pawlik, Ralph H. Hruban, Christopher L. Wolfgang, Christine A. Iacobuzio-Donahue. Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 2018; 47(2): 208 doi: 10.1097/MPA.0000000000000985
|
| 8 |
Xiang Xia, Kundong Zhang, Gang Cen, Tao Jiang, Jun Cao, Kejian Huang, Chen Huang, Qian Zhao, Zhengjun Qiu. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation ofSMAD4. Oncotarget 2015; 6(25): 21046 doi: 10.18632/oncotarget.4124
|
| 9 |
Jun Li, Yun Wang, Chaozhe Yang, Pengfei Wang, Denise K. Oelschlager, Yong Zheng, De-An Tian, William E. Grizzle, Donald J. Buchsbaum, Mei Wan. Polyethylene Glycosylated Curcumin Conjugate Inhibits Pancreatic Cancer Cell Growth through Inactivation of Jab1. Molecular Pharmacology 2009; 76(1): 81 doi: 10.1124/mol.109.054551
|
| 10 |
Silvana Debernardi, Lukasz Liszka, Chara Ntala, Katja Steiger, Irene Esposito, Emanuela Carlotti, Ann‐Marie Baker, Stuart McDonald, Trevor Graham, Branko Dmitrovic, Roger M. Feakins, Tatjana Crnogorac‐Jurcevic. Molecular characteristics of early‐onset pancreatic ductal adenocarcinoma. Molecular Oncology 2024; 18(3): 677 doi: 10.1002/1878-0261.13576
|
| 11 |
Alessandra Strom, Claire Bonal, Ruth Ashery-Padan, Naoko Hashimoto, M. Luisa Campos, Andreas Trumpp, Tetsuo Noda, Yoshiaki Kido, Francisco X. Real, Fabrizio Thorel, Pedro L. Herrera. Unique mechanisms of growth regulation and tumor suppression upon Apc inactivation in the pancreas. Development 2007; 134(15): 2719 doi: 10.1242/dev.02875
|
| 12 |
F. G. Bader, G. Auer, H.-P. Bruch, U.J. Roblick, J.K. Habermann. Hepatobiliäre und Pankreastumoren. 2010; : 38 doi: 10.1007/978-3-642-04935-4_3
|
| 13 |
Alexios Strimpakos, Muhammad W. Saif, Kostas N. Syrigos. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer and Metastasis Reviews 2008; 27(3): 495 doi: 10.1007/s10555-008-9134-y
|
| 14 |
Daniel R. Principe, Kaytlin E. Timbers, Luke G. Atia, Regina M. Koch, Ajay Rana. TGFβ Signaling in the Pancreatic Tumor Microenvironment. Cancers 2021; 13(20): 5086 doi: 10.3390/cancers13205086
|
| 15 |
Mario Tadic, Tajana Stoos-Veic, Milan Kujundzic, Petra Turcic, Gorana Aralica, Ivo Boskoski. Insulin-like growth factor 2 binding protein 3 expression on endoscopic ultrasound guided fine needle aspiration specimens in pancreatic ductal adenocarcinoma. European Journal of Gastroenterology & Hepatology 2020; 32(4): 496 doi: 10.1097/MEG.0000000000001696
|
| 16 |
Giuseppe Tonini, Francesco Pantano, Bruno Vincenzi, Armando Gabbrielli, Roberto Coppola, Daniele Santini. Molecular prognostic factors in patients with pancreatic cancer. Expert Opinion on Therapeutic Targets 2007; 11(12): 1553 doi: 10.1517/14728222.11.12.1553
|
| 17 |
R A Smith, J Tang, C Tudur-Smith, J P Neoptolemos, P Ghaneh. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. British Journal of Cancer 2011; 104(9): 1440 doi: 10.1038/bjc.2011.110
|
| 18 |
Edward Kim, Ethan V. Abel, Arunima Ghosh, Diane M. Simeone. Molecular Genetics of Pancreatic Cancer. 2013; : 117 doi: 10.1007/978-1-4614-6549-2_6
|
| 19 |
Milind Javle, Yanan Li, Dongfeng Tan, Xiaoqun Dong, Ping Chang, Siddhartha Kar, Donghui Li, John Souglakos. Biomarkers of TGF-β Signaling Pathway and Prognosis of Pancreatic Cancer. PLoS ONE 2014; 9(1): e85942 doi: 10.1371/journal.pone.0085942
|
| 20 |
Sun Jae Lee, Eunsil Yu, Young Kyung Bae, Kee-Taek Jang, Joon Mee Kim, Han-Ik Bae, Seung-Mo Hong, Ghil Suk Yoon. DPC4 Expression in the Small Intestinal Adenocarcinomas. Korean Journal of Pathology 2012; 46(5): 415 doi: 10.4132/KoreanJPathol.2012.46.5.415
|
| 21 |
Stephen P. Malkoski, Xiao-Jing Wang. Two sides of the story? Smad4 loss in pancreatic cancer versus head‐and‐neck cancer. FEBS Letters 2012; 586(14): 1984 doi: 10.1016/j.febslet.2012.01.054
|
| 22 |
Xiang Xia, Weidong Wu, Chen Huang, Gang Cen, Tao Jiang, Jun Cao, Kejian Huang, Zhengjun Qiu. SMAD4 and its role in pancreatic cancer. Tumor Biology 2015; 36(1): 111 doi: 10.1007/s13277-014-2883-z
|
| 23 |
Anak Iamaroon, Kassara Pattamapun, Siribang-on Piboonniyom. Aberrant expression of Smad4, a TGF-β signaling molecule, in oral squamous cell carcinoma. Journal of Oral Science 2006; 48(3): 105 doi: 10.2334/josnusd.48.105
|
| 24 |
Emily J. Anstadt, Ruben Carmona, Eva Berlin, Nikhil Yegya‐Raman, Sriram Venigalla, Vishruth Reddy, Graeme R. Williams, Mark R. Leibensperger, Andrzej Wojcieszynski, Brian C. Baumann, Major K. Lee, John P. Plastaras, Emma E. Furth, Loren K. Mell, James M. Metz, Edgar Ben‐Josef. SMAD4 loss predicts worse overall and distant metastasis‐free survival in patients with resected pancreatic adenocarcinoma. Cancer 2024; 130(3): 476 doi: 10.1002/cncr.35058
|
| 25 |
G. Garcea, C.P. Neal, C.J. Pattenden, W.P. Steward, D.P. Berry. Molecular prognostic markers in pancreatic cancer: A systematic review. European Journal of Cancer 2005; 41(15): 2213 doi: 10.1016/j.ejca.2005.04.044
|
| 26 |
Marie-Lucie Racu, Laetitia Lebrun, Andrea Alex Schiavo, Claude Van Campenhout, Sarah De Clercq, Lara Absil, Esmeralda Minguijon Perez, Calliope Maris, Christine Decaestecker, Isabelle Salmon, Nicky D’Haene. The Role of SMAD4 Inactivation in Epithelial–Mesenchymal Plasticity of Pancreatic Ductal Adenocarcinoma: The Missing Link?. Cancers 2022; 14(4): 973 doi: 10.3390/cancers14040973
|
| 27 |
Alixanna Norris, Murray Korc. Handbook of Cell Signaling. 2010; : 2783 doi: 10.1016/B978-0-12-374145-5.00324-7
|
| 28 |
Alexios S. Strimpakos, Kostas N. Syrigos, Muhammad Wasif Saif. The Molecular Targets for the Diagnosis and Treatment of Pancreatic Cancer. Gut and Liver 2010; 4(4): 433 doi: 10.5009/gnl.2010.4.4.433
|
| 29 |
Sarah Alghamdi, Khaled Alghaashamy, Andre Pinto. Expression of SMAD4 is Retained in Most Gynecologic Tumors with Mucinous Differentiation. International Journal of Gynecological Pathology 2020; 39(5): 493 doi: 10.1097/PGP.0000000000000637
|
| 30 |
Puneet Singh, Radhika Srinivasan, Jai Dev Wig, Bishan Das Radotra. A study of Smad4, Smad6 and Smad7 in Surgically Resected Samples of Pancreatic Ductal Adenocarcinoma and Their Correlation with Clinicopathological Parameters and Patient Survival. BMC Research Notes 2011; 4(1) doi: 10.1186/1756-0500-4-560
|
| 31 |
Zusen Wang, Yongxing Li, Shixiong Zhan, Lu Zhang, Shun Zhang, Qian Tang, Miaomiao Li, Zhen Tan, Shiguo Liu, Xiaoming Xing. SMAD4 Y353C promotes the progression of PDAC. BMC Cancer 2019; 19(1) doi: 10.1186/s12885-019-6251-7
|
| 32 |
Matthew J. Reilley, Gauri R. Varadhachary. Multimodality Management of Borderline Resectable Pancreatic Cancer. 2016; : 91 doi: 10.1007/978-3-319-22780-1_6
|
| 33 |
Jin-Dao Wang, Ketao Jin, Xiao-Ying Chen, Jie-Qing Lv, Ke-Wei Ji. Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis. Oncotarget 2017; 8(10): 16704 doi: 10.18632/oncotarget.14335
|
| 34 |
Hui Su, Cunchuan Wang. Prognostic value of SMAD4 in resectable pancreatic cancer. Postępy Higieny i Medycyny Doświadczalnej 2022; 76(1): 324 doi: 10.2478/ahem-2022-0036
|
| 35 |
Richard A. Smith, Jane V. Butler, John P. Neoptolemos. Patient Surveillance After Cancer Treatment. 2013; : 129 doi: 10.1007/978-1-60327-969-7_24
|
| 36 |
Yiping Du, Xin Zhou, Zebo Huang, Tianzhu Qiu, Jian Wang, Wei Zhu, Tongshan Wang, Ping Liu, Zoran Culig. Meta-Analysis of the Prognostic Value of Smad4 Immunohistochemistry in Various Cancers. PLoS ONE 2014; 9(10): e110182 doi: 10.1371/journal.pone.0110182
|
| 37 |
Clarissa C Pasiliao, Che-Wei A Chang, Brent W Sutherland, Shannon M Valdez, David Schaeffer, Donald T Yapp, Sylvia S W Ng. The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion. BMC Cancer 2015; 15(1) doi: 10.1186/s12885-015-1251-8
|